Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

smoke.cannabis.hookah.weed_.jpg

Growing Cannabis Use in Arthritis Patients

The National Databank for Rheumatic Diseases reports a significant increased in cannabis use amongst arthritis patients between 2014-2019, suggesting patients are more frequently engaged in self-management of pain and the unmet need for a pain relieving, opioid-sparing alternative.

Read Article
Jo1.gottrons.jpg

FDA Approves IVIG in Dermatomyositis

The U.S. Food and Drug Administration (FDA) has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM).

Read Article
infused.jpg

Canakinumab Fails to Improve COVID-19 Survival

JAMA has published the findings of trial wherein the anti–interleukin-1β antibody canakinumab (CAN) failed to improve survival in patients hospitalized with severe COVID-19.

Read Article
artangiogca.jpg

ACR/Vasculitis Foundation Guideline for Giant Cell Arteritis and Takayasu Arteritis

The ACR and the Vasculitis Foundation have published their evidence-based recommendations and expert guidance for the management of GCA and Takayasu arteritis. These recommendations address a variety of clinical questions and scenarios including diagnostic testing, imaging, treatments, and surgical interventions. Recommendations for GCA and TAK include support for the use of glucocorticoid-sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of glucocorticoids as initial therapy.

Read Article
Nail, pitting, psoriasis, onycholysis

Impact of Nail Psoriasis on Psoriatic Arthritis

Mease and colleagues have shown that psoriatic arthritis (PsA) patients with nail involvement have worse disease and outcomes than those without nail psoriasis.

Read Article
RheumNow Podcast square

RheumNow Podcast – What Not to Do (7.16.2021)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
hip, OA, AVN

Osteonecrosis in Lupus

A single center analysis of systemic lupus erythematosus (SLE) patients found symptomatic osteonecrosis (ON) in nearly 10%.

Read Article
JIA_0.jpg

Arthritis as a Harbinger of Pediatric Cancer

Lancet Rheumatology has published a cohort analysis showing that a small but significant subset of children presenting with arthralgia or arthritis may have a pediatric malignancy.

Read Article
ANCA, vasculitis, test

ACR/Vasculitis Foundation 2021 Guidelines for ANCA–Associated Vasculitis

Chung et al have published the 2021 treatment guielines for the management of antineutrophil cytoplasmic antibody–associated vasculitis, including granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. These guidelines are put forth by the ACR and the Vasculitis Foundation as benchmark guidance to assist health care professionals in managing AAV.  

Read Article
fetus,defect,baby,malformation

Potential Birth Defects with Hydroxychloroquine

Hydroxychloroquine (HCQ) is one of the safest meds used in rheumatology, but there is new claims data suggesting a small increase in the risk of malformations associated with first-trimester HCQ use.

Read Article
×